-+ 0.00%
-+ 0.00%
-+ 0.00%

Edding Genor receives US$ 48.42 million from sale of Candid stake in UCB deal

PUBT·07/16/2026 14:21:30
Listen to the news
Edding Genor receives US$ 48.42 million from sale of Candid stake in UCB deal
  • Edding Genor received USD 48.42 million on July 16 from selling its entire stake in Candid Therapeutics through UCB’s completed acquisition.
  • The stake comprised 12,499,997 Candid common shares, about 2.29% of the company, converted into cash consideration at closing.
  • UCB’s deal values total closing consideration at about USD 1.95 billion, subject to customary adjustments.
  • Edding Genor may receive additional proceeds tied to its pro rata share of up to USD 200 million in development milestones.
  • The disposal generated a recognized gain of USD 33.8 million, pending final audit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12247423), on July 16, 2026, and is solely responsible for the information contained therein.